MedTrace Logo

The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC

NCT04839055 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-04-09

No results posted yet for this study

Summary

The purpose of this study is to compare the therapy effects and clinical safety of a regulatory metabolic compound, coenzyme A (CoA) with a marketed drug, abiraterone, in Chinese patients with castration-resistant prostate cancer (CRPC) .

Conditions

  • Castration-resistant Prostate Cancer

Interventions

DRUG

Coenzyme A Combined With Abiraterone

Abiraterone 4 pieces per day. Coenzyme A 200U

DRUG

Abiraterone

Abiraterone

Sponsors & Collaborators

  • Affiliated Hospital of Jiangnan University

    collaborator OTHER

  • Jiangnan University

    lead OTHER

Principal Investigators

  • YongQuan Chen, MD · Jiangnan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-18
Primary Completion
2021-04-01
Completion
2021-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04839055 on ClinicalTrials.gov